OverviewSuggest Edit

WuXi AppTec (药明康德, formerly known as WuXi PharmaTech) is a company providing research, development, and manufacturing services to discover and manufacture small molecule drugs and cell and gene therapies. It offers drug discovery, pre-clinical development, and clinical processes research, as well as synthetic chemistry, biology, medicinal chemistry, analytical chemistry, toxicology, bioanalysis, and testing services. The company serves pharmaceutical, biotech, and medical device industries.

TypePublic
Founded2000
HQShanghai, CN
Websitewuxiapptec.com
Employee Ratings3.1
Overall CultureF

Latest Updates

Employees (est.) (Apr 2021)27,272(+4%)
Job Openings194
Revenue (FY, 2020)¥16.5 B(+29%)
Share Price (Sept 2021)¥152.4(+6%)
Cybersecurity ratingAMore

Key People/Management at WuXi AppTec

Ge Li

Ge Li

Chairman and CEO
Edward Hu

Edward Hu

Vice Chairman, Global Chief Investment Officer
Steve Yang

Steve Yang

Co-CEO
Minzhang Chen

Minzhang Chen

Executive Vice President, CEO of STA
Shuhui Chen

Shuhui Chen

Executive Vice President, Chief Scientific Officer, Head of DDSU
Zhaohui Zhang

Zhaohui Zhang

China Chief Operating Officer, Executive Vice President
Show more

WuXi AppTec Office Locations

WuXi AppTec has offices in Shanghai, Beijing, Changzhou Shi, Chengdu and in 14 other locations
Shanghai, CN (HQ)
288 Fute Middle Rd, Pudong Xinqu
Beijing, CN
block c, Zhao Tai Guo Ji Zhong Xin, Chaoyang Qu
Changzhou Shi, CN
589 North Yulong Road, Xinbei District
Chengdu, CN
No.388 Haifa Road, Chengdu Cross-Strait Science & Technology Industrial Development Park, Wenjiang District
Nantong, CN
699 Huashi Nan Road, Qidong Economic Development Zone
Shanghai, CN
8F&19F, Building, 388 Madang Rd, Huangpu Qu
Show all (24)

WuXi AppTec Financials and Metrics

WuXi AppTec Revenue

Embed Graph
View revenue for all periods
WuXi AppTec's revenue was reported to be ¥16.54 b in FY, 2020 which is a 28.5% increase from the previous period.
CNY

Revenue (H1, 2021)

10.5b

Gross profit (H1, 2021)

3.9b

Gross profit margin (H1, 2021), %

36.9%

Net income (H1, 2021)

2.7b

EBIT (H1, 2021)

3.1b

Market capitalization (17-Sept-2021)

371.8b

Closing stock price (17-Sept-2021)

152.4

Cash (30-Jun-2021)

9.8b

EV

368.2b
WuXi AppTec's current market capitalization is ¥371.8 b.
Annual
CNYFY, 2018FY, 2019FY, 2020

Revenue

9.6b12.9b16.5b

Revenue growth, %

24%34%28%

Cost of goods sold

5.8b7.9b10.3b

Gross profit

3.8b5.0b6.3b
Half Year
CNYH1, 2019H1, 2020H1, 2021

Revenue

5.9b7.2b10.5b

Cost of goods sold

3.6b4.6b6.7b

Gross profit

2.3b2.7b3.9b

Gross profit Margin, %

39%37%37%
Annual
CNYFY, 2018FY, 2019FY, 2020

Cash

5.8b5.2b10.2b

Accounts Receivable

2.0b3.0b3.6b

Prepaid Expenses

42.8m24.0m21.3m

Inventories

854.8m1.2b1.9b
Half Year
CNYH1, 2019H1, 2020H1, 2021

Cash

3.7b2.8b9.8b

Accounts Receivable

2.5b3.3b4.1b

Prepaid Expenses

46.6m30.4m32.9m

Inventories

972.5m1.7b2.8b
Annual
CNYFY, 2018FY, 2019FY, 2020

Depreciation and Amortization

645.2m963.4m1.1b

Inventories

(207.0m)(378.9m)(516.6m)

Accounts Payable

254.2m618.8m133.3m

Cash From Operating Activities

1.5b2.5b3.8b
Half Year
CNYH1, 2019H1, 2020H1, 2021

Cash From Operating Activities

877.7m1.4b2.1b

Purchases of PP&E

(1.0b)(1.1b)

Cash From Investing Activities

(2.6b)(2.5b)(2.5b)

Long-term Borrowings

(192.6m)(1.7b)
CNYFY, 2018

Revenue/Employee

542.2k

Financial Leverage

1.2 x
Show all financial metrics

WuXi AppTec Operating Metrics

WuXi AppTec's New Customers was reported to be 1.3 k in FY, 2020. WuXi AppTec's Active Customers was reported to be 4.2 k in FY, 2020.
FY, 2018FY, 2019FY, 2020

New Customers

1.4 k1.2 k1.3 k

Active Customers

3.5 k3.9 k4.2 k

DNA Encoded Library Compounds

80 b90 b90 b

Customers (DNA Encoded Library) to Date

11077
Show all operating metrics

WuXi AppTec Acquisitions / Subsidiaries

Company NameDateDeal Size
Oxford GeneticsMay 01, 2021
OXGENEMarch 02, 2021
PharmapaceMay 05, 2019
ResearchPoint GlobalOctober 17, 2017
HD BiosciencesJanuary 19, 2017
CreluxApril 15, 2016
NextCODE HealthJanuary 09, 2015$65 m
Changzhou SynTheAll Pharmaceutical Co.
Shanghai STA Pharmaceutical R&D Co.
Shanghai SynTheAll Pharmaceutical Co.
Show more

WuXi AppTec Revenue Breakdown

Embed Graph

WuXi AppTec revenue breakdown by business segment: 9.2% from U.S.-based Laboratory Services, 7.1% from Clinical Research and Other CRO Services, 31.9% from CMO/CDMO Services, 51.7% from China-based Laboratory Services and 0.1% from Other

WuXi AppTec revenue breakdown by geographic segment: 25.1% from China, 53.6% from United States, 16.0% from Europe and 5.3% from Other

Human Capital Metrics

WuXi AppTec's employees are reported to be approximately 82% female and 18% male.
Embed Graph
Show all human capital metrics

WuXi AppTec Cybersecurity Score

Cybersecurity ratingPremium dataset

A

91/100

SecurityScorecard logo

WuXi AppTec Online and Social Media Presence

Embed Graph

WuXi AppTec Company Culture

  • Overall Culture

    F

    41/100

  • CEO Rating

    F

    40/100

  • Compensation

    F

    10/100

Learn more on Comparably

WuXi AppTec News and Updates

WuXi AppTec Receives AA ESG Rating from MSCI

SHANGHAI, Sept. 5, 2021 /PRNewswire/ -- WuXi AppTec ("the Company") is pleased to announce that Morgan Stanley Capital International ("MSCI") has upgraded its MSCI ESG Rating to AA. The Company also received outstanding scores in the areas of "corporate governance" and "product safety and...

WuXi AppTec Reports Strong 2021 Interim Results

WuXi AppTec (stock code: 603259.SH / 2359.HK), a company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients, is ple…

WuXi AppTec Reports Strong 2021 Interim Results

Revenue Up 45.7% Year-Over-Year to RMB10,537 Million Net Profit Attributable to Owners of the Company Up 55.8% Year-Over-Year to RMB2,675 Million Diluted EPS Up 46.8% Year-Over-Year to RMB0.91 Adjusted Non-IFRS[1] Net Profit Attributable to Owners of the Company Up 67.8% Year-Over-Year to...

Aptamer Group and WuXi AppTec Research Service Division collaborate to identify new Optimerâ„¢ enabled therapeutics

Aptamer Group, the developer of Optimer™ therapeutics and diagnostics, and WuXi AppTec Research Service Division, an integrated chemistry and biology research platform, today announce a research collaboration to identify new Optimer™-enabled therapeutics.

Global Clinical Trial Market (2020 to 2026) - Featuring ICON, Wuxi AppTec and SGS Among Others

Dublin, July 22, 2021 (GLOBE NEWSWIRE) -- The "Clinical Trial Market, Global Forecast Impact of COVID-19, Industry Trends by Phases, Study Design, Region, Opportunity Company Overview, Revenue" report has been added to ResearchAndMarkets.com's offering. The clinical trial is a human medical study …

Aptamer Group and WuXi AppTec Research Service Division collaborate to identify new Optimerâ„¢ enabled therapeutics

Aptamer Group and WuXi AppTec Research Service Division collaborate to identify new Optimerâ„¢ enabled therapeutics
Show more

WuXi AppTec Frequently Asked Questions

  • When was WuXi AppTec founded?

    WuXi AppTec was founded in 2000.

  • Who are WuXi AppTec key executives?

    WuXi AppTec's key executives are Ge Li, Edward Hu and Steve Yang.

  • How many employees does WuXi AppTec have?

    WuXi AppTec has 27,272 employees.

  • What is WuXi AppTec revenue?

    Latest WuXi AppTec annual revenue is ¥16.5 b.

  • What is WuXi AppTec revenue per employee?

    Latest WuXi AppTec revenue per employee is ¥606.3 k.

  • Who are WuXi AppTec competitors?

    Competitors of WuXi AppTec include Yabao Pharmaceutical, Hetero and Pharmaron.

  • Where is WuXi AppTec headquarters?

    WuXi AppTec headquarters is located at 288 Fute Middle Rd, Pudong Xinqu, Shanghai.

  • Where are WuXi AppTec offices?

    WuXi AppTec has offices in Shanghai, Beijing, Changzhou Shi, Chengdu and in 14 other locations.

  • How many offices does WuXi AppTec have?

    WuXi AppTec has 24 offices.